Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Oligonucleotide therapeutic approaches for Huntington disease Sah DW; Aronin NJ Clin Invest 2011[Feb]; 121 (2): 500-7Huntington disease is an autosomal dominant neurodegenerative disorder caused by a toxic expansion in the CAG repeat region of the huntingtin gene. Oligonucleotide approaches based on RNAi and antisense oligonucleotides provide promising new therapeutic strategies for direct intervention through reduced production of the causative mutant protein. Allele-specific and simultaneous mutant and wild-type allele-lowering strategies are being pursued with local delivery to the brain, each with relative merits. Delivery remains a key challenge for translational success, especially with chronic therapy. The potential of disease-modifying oligonucleotide approaches for Huntington disease will be revealed as they progress into clinical trials.|Clinical Trials as Topic[MESH]|Gene Silencing[MESH]|Humans[MESH]|Huntingtin Protein[MESH]|Huntington Disease/*drug therapy/genetics[MESH]|Mutation[MESH]|Nerve Tissue Proteins/genetics/metabolism[MESH]|Neurons/pathology/physiology[MESH]|Nuclear Proteins/genetics/metabolism[MESH]|Oligonucleotides, Antisense/therapeutic use[MESH]|Oligonucleotides/*therapeutic use[MESH]|RNA Interference[MESH]|Trinucleotide Repeat Expansion[MESH] |
